- Home
- CVKD vs ENLV Comparison
CVKD vs ENLV Comparison
Compare CVKD & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- ENLV
- Stock Information
- Founded
- CVKD 2022
- ENLV 2005
- Country
- CVKD United States
- ENLV Israel
- Employees
- CVKD N/A
- ENLV N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- ENLV Health Care
- Exchange
- CVKD Nasdaq
- ENLV Nasdaq
- Market Cap
- CVKD 26.3M
- ENLV 31.5M
- IPO Year
- CVKD 2023
- ENLV 1995
- Fundamental
- Price
- CVKD $17.04
- ENLV $1.09
- Analyst Decision
- CVKD Strong Buy
- ENLV Strong Buy
- Analyst Count
- CVKD 2
- ENLV 2
- Target Price
- CVKD $46.00
- ENLV $9.50
- AVG Volume (30 Days)
- CVKD 84.2K
- ENLV 173.7K
- Earning Date
- CVKD 11-07-2024
- ENLV 11-30-2024
- Dividend Yield
- CVKD N/A
- ENLV N/A
- EPS Growth
- CVKD N/A
- ENLV N/A
- EPS
- CVKD N/A
- ENLV N/A
- Revenue
- CVKD N/A
- ENLV N/A
- Revenue This Year
- CVKD N/A
- ENLV N/A
- Revenue Next Year
- CVKD N/A
- ENLV N/A
- P/E Ratio
- CVKD N/A
- ENLV N/A
- Revenue Growth
- CVKD N/A
- ENLV N/A
- 52 Week Low
- CVKD $5.40
- ENLV $1.08
- 52 Week High
- CVKD $32.55
- ENLV $4.59
- Technical
- Relative Strength Index (RSI)
- CVKD 57.77
- ENLV 27.79
- Support Level
- CVKD $16.25
- ENLV $1.13
- Resistance Level
- CVKD $19.97
- ENLV $1.33
- Average True Range (ATR)
- CVKD 1.80
- ENLV 0.10
- MACD
- CVKD -0.04
- ENLV -0.02
- Stochastic Oscillator
- CVKD 54.70
- ENLV 6.52
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.